Catalogo Articoli (Spogli Riviste)

OPAC HELP

Titolo:
Additive effects of human recombinant interleukin-11 and granulocyte colony-stimulating factor in experimental gram-negative sepsis
Autore:
Opal, SM; Jhung, JW; Keith, JC; Goldman, SJ; Palardy, JE; Parejo, NA;
Indirizzi:
Mem Hosp Rhode Isl, Div Infect Dis, Pawtucket, RI 02860 USA Mem Hosp RhodeIsl Pawtucket RI USA 02860 ct Dis, Pawtucket, RI 02860 USA Mem Hosp Rhode Isl, Dept Pathol, Pawtucket, RI 02860 USA Mem Hosp Rhode Isl Pawtucket RI USA 02860 Pathol, Pawtucket, RI 02860 USA Brown Univ, Sch Med, Providence, RI 02912 USA Brown Univ Providence RI USA 02912 niv, Sch Med, Providence, RI 02912 USA Genet Inst, Cambridge, MA 02140 USA Genet Inst Cambridge MA USA 02140Genet Inst, Cambridge, MA 02140 USA
Titolo Testata:
BLOOD
fascicolo: 10, volume: 93, anno: 1999,
pagine: 3467 - 3472
SICI:
0006-4971(19990515)93:10<3467:AEOHRI>2.0.ZU;2-0
Fonte:
ISI
Lingua:
ENG
Soggetto:
NON-HODGKINS-LYMPHOMA; TUMOR-NECROSIS-FACTOR; FACTOR G-CSF; GROWTH-FACTOR; MOLECULAR-CLONING; CONTROLLED TRIAL; CHEMOTHERAPY; RECEPTOR; CYTOKINE; CANCER;
Tipo documento:
Article
Natura:
Periodico
Settore Disciplinare:
Clinical Medicine
Life Sciences
Citazioni:
36
Recensione:
Indirizzi per estratti:
Indirizzo: Opal, SM MemAHosp Rhode Isl, Div Infect Dis, 111 Brewster St, Pawtucket, RI 02860 US Mem Hosp Rhode Isl 111 Brewster St Pawtucket RI USA 02860 2860 US
Citazione:
S.M. Opal et al., "Additive effects of human recombinant interleukin-11 and granulocyte colony-stimulating factor in experimental gram-negative sepsis", BLOOD, 93(10), 1999, pp. 3467-3472

Abstract

Recombinant human granulocyte colony-stimulating factor (rhG-CSF) is widely used to promote granulocyte recovery from a variety of pathologic states. Recombinant human interleukin-11 (rhIL-11) has recently become available clinically as a platelet restorative agent after myelosuppressive chemotherapy. Preclinical data has shown that rhIL-11 limits mucosal injury after chemotherapy and attenuates the proinflammatory cytokine response. The potential efficacy of combination therapy with recombinant human forms of rhIL-11 and rhG-CSF was studied in a neutropenic rat model of Pseudomonas aeruginosa sepsis. At the onset of neutropenia, animals were randomly assigned to receive either rhG-CSF at a dose of 200 mu g/kg subcutaneously every 24 hoursfor 7 days; rhIL-11 at 200 mu g/kg subcutaneously every 24 hours for 7 days; the combination of both rhG-CSF and rhIL-11; or saline control. Animals were orally colonized with Pseudomonas aeruginosa 12.4.4 and then given a myelosuppressive dose of cyclophosphamide. rhG-CSF resulted in a slight increase in absolute neutrophil counts (ANC), but did not provide a survival advantage (0 of 12, 0% survival) compared with the placebo group (1 of 12, 8%survival). rhIL-11 was partially protective (4 of 10, 40% survival); the combination of rhG-CSF and rhIL-11 resulted in a survival rate of 80% (16 of20; P <.001), rhIL-11 alone or in combination with rhG-CSF resulted in preservation of gastrointestinal mucosal integrity (P <.001), lower circulating endotoxin levels (P <.01), and reduced quantitative levels of P. aeruginosa in quantitative organ cultures. These results indicate that the combination of rhIL-11 and rhG-CSF is additive as a treatment strategy in the prevention and treatment of experimental Gram-negative sepsis in immunocompromised animals. This combination may prove to be efficacious in the prevention of severe sepsis in neutropenic patients. (C) 1999 by The American Society of Hematology.

ASDD Area Sistemi Dipartimentali e Documentali, Università di Bologna, Catalogo delle riviste ed altri periodici
Documento generato il 30/05/20 alle ore 15:09:07